Novartis agreed to acquire Excellergy for up to $2 billion, aiming to strengthen its immunology strategy and build a next-generation anti-IgE franchise that could serve as a successor to Xolair. The deal is structured around an upfront payment plus milestone consideration, with closing expected in the second half of 2026 pending regulatory approvals. Excellergy’s lead asset, Exl-111, is a half-life extended anti-IgE antibody in Phase I. Novartis said the program is designed to go beyond conventional anti-IgE therapy by delivering faster and deeper suppression of IgE signaling and improved symptom control, including through a mechanism that targets receptor-bound IgE to drive FcεRIα downregulation. The transaction arrives shortly after Excellergy raised a $70 million Series A earlier this year, indicating how quickly early clinical assets can draw major-pharma attention when differentiated biology aligns with commercial needs. Xolair’s exposure to biosimilar competition heightens the urgency for the next wave. For dealmakers and alliance teams, the Excellergy buyout is a reminder that immunology M&A is accelerating around platformable mechanisms that can potentially expand dosing convenience and depth of receptor engagement.